Use of infliximab and other biologics in Behçet disease.
Behçet disease is a multisystem vasculitis characterised by recurrent oral ulceration in conjunction with other manifestations. Neurological involvement or neuro-Behçet disease is not common, but typically affects young men at its onset between the ages of 20 and 40 with significant long-term morbidity and mortality. There is substantial case literature to support the use of tumour necrosis factor antagonists, notably infliximab, in the treatment of neuro-Behçet disease.
Department of Clinical Immunology and Allergy, Royal North Shore Hospital, Sydney, New South Wales, Australia.
J
J
Li
S
S
Fernando
G
G
Herkes
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000628:therapy; D001688:Biological Products / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D057210:Delayed Diagnosis; D018450:Disease Progression; D059949:HLA-B51 Antigen / Q000032:analysis; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D051346:Mobility Limitation; D020335:Paraparesis / Q000209:etiology / Q000534:rehabilitation; D010956:Plasmapheresis; D011239:Prednisolone / Q000627:therapeutic use; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D001688:Biological Products; D059949:HLA-B51 Antigen; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D011239:Prednisolone; D000069285:Infliximab; D008775:Methylprednisolone
Behçet disease; infliximab; neuro-Behçet